vs

Side-by-side financial comparison of ARTS WAY MANUFACTURING CO INC (ARTW) and BioAge Labs, Inc. (BIOA). Click either name above to swap in a different company.

ARTS WAY MANUFACTURING CO INC is the larger business by last-quarter revenue ($5.1M vs $3.1M, roughly 1.6× BioAge Labs, Inc.). ARTS WAY MANUFACTURING CO INC runs the higher net margin — -12.7% vs -842.9%, a 830.1% gap on every dollar of revenue. ARTS WAY MANUFACTURING CO INC produced more free cash flow last quarter ($-1.0M vs $-28.4M).

Art's Way Manufacturing is an American producer of agricultural machinery, modular buildings and cutting tools under the brand names Art's Way, Art's Way Scientific and American Carbide Tool. The firm previously manufactured OEM feed blowers sold by Case New Holland.

Altos Labs, Inc. is an American biotechnology research company. Altos Labs' goal is to develop life extension therapies that can halt or reverse the human aging process. Specialized cell therapies based on induced pluripotent stem cells are to be developed for this purpose. Russian-born technology businessman Yuri Milner, along with investors including Jeff Bezos, funded the company in 2021, operations started in 2022.

ARTW vs BIOA — Head-to-Head

Bigger by revenue
ARTW
ARTW
1.6× larger
ARTW
$5.1M
$3.1M
BIOA
Higher net margin
ARTW
ARTW
830.1% more per $
ARTW
-12.7%
-842.9%
BIOA
More free cash flow
ARTW
ARTW
$27.3M more FCF
ARTW
$-1.0M
$-28.4M
BIOA

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ARTW
ARTW
BIOA
BIOA
Revenue
$5.1M
$3.1M
Net Profit
$-645.5K
$-25.9M
Gross Margin
18.6%
Operating Margin
-11.2%
-923.4%
Net Margin
-12.7%
-842.9%
Revenue YoY
-17.9%
Net Profit YoY
-177.6%
EPS (diluted)
$-0.13
$-0.72

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ARTW
ARTW
BIOA
BIOA
Q4 25
$5.1M
$3.1M
Q3 25
$6.4M
$2.1M
Q2 25
$6.3M
$2.4M
Q1 25
$5.1M
$1.5M
Q4 24
$6.2M
Q3 24
$5.9M
$0
Q2 24
$6.7M
Q1 24
$5.7M
Net Profit
ARTW
ARTW
BIOA
BIOA
Q4 25
$-645.5K
$-25.9M
Q3 25
$254.1K
$-20.2M
Q2 25
$1.5M
$-21.6M
Q1 25
$-55.8K
$-12.9M
Q4 24
$832.0K
Q3 24
$-26.2K
$-23.4M
Q2 24
$-33.3K
Q1 24
$-465.0K
Gross Margin
ARTW
ARTW
BIOA
BIOA
Q4 25
18.6%
Q3 25
27.5%
Q2 25
32.5%
Q1 25
29.1%
Q4 24
36.1%
Q3 24
28.9%
Q2 24
28.3%
Q1 24
25.7%
Operating Margin
ARTW
ARTW
BIOA
BIOA
Q4 25
-11.2%
-923.4%
Q3 25
5.4%
-1126.6%
Q2 25
8.1%
-1027.0%
Q1 25
0.0%
-1133.4%
Q4 24
8.4%
Q3 24
2.6%
Q2 24
2.5%
Q1 24
-6.6%
Net Margin
ARTW
ARTW
BIOA
BIOA
Q4 25
-12.7%
-842.9%
Q3 25
4.0%
-982.0%
Q2 25
23.4%
-894.0%
Q1 25
-1.1%
-891.0%
Q4 24
13.5%
Q3 24
-0.4%
Q2 24
-0.5%
Q1 24
-8.1%
EPS (diluted)
ARTW
ARTW
BIOA
BIOA
Q4 25
$-0.13
$-0.72
Q3 25
$0.05
$-0.56
Q2 25
$0.29
$-0.60
Q1 25
$-0.01
$-0.36
Q4 24
$0.17
Q3 24
$-0.01
$-6.70
Q2 24
$-0.01
Q1 24
$-0.09

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ARTW
ARTW
BIOA
BIOA
Cash + ST InvestmentsLiquidity on hand
$4.8K
$281.1M
Total DebtLower is stronger
$2.5M
Stockholders' EquityBook value
$13.3M
$272.1M
Total Assets
$22.5M
$294.9M
Debt / EquityLower = less leverage
0.19×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ARTW
ARTW
BIOA
BIOA
Q4 25
$4.8K
$281.1M
Q3 25
$6.0K
$285.8M
Q2 25
$4.5K
$297.3M
Q1 25
$4.1K
$320.5M
Q4 24
$1.9K
Q3 24
$5.1K
$334.5M
Q2 24
$4.5K
Q1 24
$2.5K
Total Debt
ARTW
ARTW
BIOA
BIOA
Q4 25
$2.5M
Q3 25
Q2 25
Q1 25
$7.1M
Q4 24
$2.1M
Q3 24
$2.7M
$9.9M
Q2 24
$2.7M
Q1 24
$2.7M
Stockholders' Equity
ARTW
ARTW
BIOA
BIOA
Q4 25
$13.3M
$272.1M
Q3 25
$13.9M
$277.5M
Q2 25
$13.6M
$294.8M
Q1 25
$12.1M
$313.2M
Q4 24
$12.1M
Q3 24
$11.3M
$313.7M
Q2 24
$11.2M
Q1 24
$11.2M
Total Assets
ARTW
ARTW
BIOA
BIOA
Q4 25
$22.5M
$294.9M
Q3 25
$21.8M
$305.1M
Q2 25
$20.9M
$322.1M
Q1 25
$21.0M
$343.8M
Q4 24
$21.2M
Q3 24
$23.5M
$337.4M
Q2 24
$23.2M
Q1 24
$24.3M
Debt / Equity
ARTW
ARTW
BIOA
BIOA
Q4 25
0.19×
Q3 25
Q2 25
Q1 25
0.02×
Q4 24
0.17×
Q3 24
0.24×
0.03×
Q2 24
0.24×
Q1 24
0.24×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ARTW
ARTW
BIOA
BIOA
Operating Cash FlowLast quarter
$-889.2K
$-28.3M
Free Cash FlowOCF − Capex
$-1.0M
$-28.4M
FCF MarginFCF / Revenue
-20.6%
-921.5%
Capex IntensityCapex / Revenue
3.0%
3.6%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-1.5M
$-82.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ARTW
ARTW
BIOA
BIOA
Q4 25
$-889.2K
$-28.3M
Q3 25
$-1.3M
$-16.0M
Q2 25
$1.4M
$-20.0M
Q1 25
$-101.8K
$-17.4M
Q4 24
$1.2M
Q3 24
$282.4K
Q2 24
$1.2M
Q1 24
$-99.3K
Free Cash Flow
ARTW
ARTW
BIOA
BIOA
Q4 25
$-1.0M
$-28.4M
Q3 25
$-1.5M
$-16.1M
Q2 25
$1.2M
$-20.1M
Q1 25
$-184.5K
$-17.8M
Q4 24
$1.1M
Q3 24
$180.5K
Q2 24
$1.0M
Q1 24
$-380.4K
FCF Margin
ARTW
ARTW
BIOA
BIOA
Q4 25
-20.6%
-921.5%
Q3 25
-23.8%
-782.2%
Q2 25
19.3%
-834.5%
Q1 25
-3.6%
-1226.0%
Q4 24
17.6%
Q3 24
3.1%
Q2 24
15.1%
Q1 24
-6.6%
Capex Intensity
ARTW
ARTW
BIOA
BIOA
Q4 25
3.0%
3.6%
Q3 25
4.1%
1.1%
Q2 25
2.1%
6.6%
Q1 25
1.6%
29.4%
Q4 24
1.8%
Q3 24
1.7%
Q2 24
3.4%
Q1 24
4.9%
Cash Conversion
ARTW
ARTW
BIOA
BIOA
Q4 25
Q3 25
-4.99×
Q2 25
0.91×
Q1 25
Q4 24
1.44×
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ARTW
ARTW

Agricultural Products$2.8M55%
Modular Buildings$2.2M44%

BIOA
BIOA

Segment breakdown not available.

Related Comparisons